Natural killer (Nk) cells and anti-tumor therapeutic mab: Unexplored interactions

Journal of Leukocyte Biology

Volumn 99, Issue 1, 2016, Pages 87-96

  Battella, Simone ^a   Cox, Maria Christina ^c   Santoni, Angela ^b   Palmieri, Gabriella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ADCC; Chemoimmunotherapy; Fc Rs; Rituximab

Indexed keywords

CD20 ANTIBODY; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CELL INTERACTION; CLINICAL PRACTICE; DRUG EFFICACY; HUMAN; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STIMULATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL COMMUNICATION; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84953449698     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5VMR0415-141R     Document Type: Article

References (216)

1. Cheson, B. D., Leonard, J. P. (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N. Engl. J. Med. 359, 613–626
2. Ferris, R. L., Jaffee, E. M., Ferrone, S. (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 4390–4399
3. Scott, A. M., Wolchok, J. D., Old, L. J. (2012) Antibody therapy of cancer. Nat. Rev. Cancer 12, 278–287
4. Sliwkowski, M. X., Mellman, I. (2013) Antibody therapeutics in cancer. Science 341, 1192–1198
5. Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J. M., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J. P., Agostinis, P., Apte, R. N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J. Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M. P., Coussens, L., Dhodapkar, M. V., Eggermont, A. M., Fearon, D. T., Fridman, W. H., Fučíková, J., Gabrilovich, D. I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J. M., Klein, E., Knuth, A., Lewis, C. E., Liblau, R., Lotze, M. T., Lugli, E., Mach, J. P., Mattei, F., Mavilio, D., Melero, I., Melief, C. J., Mittendorf, E. A., Moretta, L., Odunsi, A., Okada, H., Palucka, A. K., Peter, M. E., Pienta, K. J., Porgador, A., Prendergast, G. C., Rabinovich, G. A., Restifo, N. P., Rizvi, N., Sautés-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M. J., Speiser, D. E., Spisek, R., Srivastava, P. K., Talmadge, J. E., Tartour, E., Van Der Burg, S. H., Van Den Eynde, B. J., Vile, R., Wagner, H., Weber, J. S., Whiteside, T. L., Wolchok, J. D., Zitvogel, L., Zou, W., Kroemer, G. (2014) Classification of current anticancer immunotherapies. Oncotarget 5, 12472–12508
6. Bianchini, G., Gianni, L. (2014) The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 15, e58–e68
7. Glennie, M. J., French, R. R., Cragg, M. S., Taylor, R. P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823–3837
8. Weiner, G. J. (2010) Rituximab: mechanism of action. Semin. Hematol. 47, 115–123
9. Boross, P., Leusen, J. H. (2012) Mechanisms of action of CD20 antibodies. Am. J. Cancer Res. 2, 676–690
10. Bakema, J. E., van Egmond, M. (2014) Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr. Top. Microbiol. Immunol. 382, 373–392
11. McLaughlin, P., Grillo-L ópez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., Dallaire, B. K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833
12. Molina, A. (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu. Rev. Med. 59, 237–250
13. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H., Stilgenbauer, S.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164–1174
14. Maloney, D. G. (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366, 2008–2016
15. Lim, S. H., Levy, R. (2014) Translational medicine in action: anti-CD20 therapy in lymphoma. J. Immunol. 193, 1519–1524
16. Cai, Q., Westin, J., Fu, K., Desai, M., Zhang, L., Huang, H., Jiang, W., Liang, R., Qian, Z., Champlin, R. E., Wang, M. (2014) Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann. Hematol. 93, 541–556
17. Taylor, R. P., Lindorfer, M. A. (2014) Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol. Pharmacol. 86, 485–491
18. Martelli, M., Ferreri, A. J., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., Pileri, S. A. (2013) Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87, 146–171
19. Meyer, S., Leusen, J. H., Boross, P. (2014) Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 6, 1133–1144
20. Taylor, R. P., Lindorfer, M. A. (2014) The role of complement in mAbbased therapies of cancer. Methods 65, 18–27
21. Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., Costa, A., Fagnoni, F. F. (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67, 11991–11999
22. Golay, J., Introna, M. (2012) Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch. Biochem. Biophys. 526, 146–153
23. Clynes, R. A., Towers, T. L., Presta, L. G., Ravetch, J. V. (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443–446
24. Nimmerjahn, F., Ravetch, J. V. (2006) Fcgamma receptors: old friends and new family members. Immunity 24, 19–28
25. Bruhns, P. (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649
26. Seidel, U. J., Schlegel, P., Lang, P. (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol. 4, 76
27. White, A. L., Beers, S. A., Cragg, M. S. (2014) FcgRIIB as a key determinant of agonistic antibody efficacy. Curr. Top. Microbiol. Immunol. 382, 355–372
28. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H. (2002) Therapeutic activity of humanized anti- CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754–758
29. Weng, W. K., Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940–3947
30. Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., Byrd, J. C. (2004) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103, 1472–1474
31. Treon, S. P., Hansen, M., Branagan, A. R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S. R., Touroutoglou, N., Turnbull, B., Anderson, K. C., Maloney, D. G., Fox, E. A. (2005) Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr¨om’s macroglobulinemia. J. Clin. Oncol. 23, 474–481
32. Kim, D. H., Jung, H. D., Kim, J. G., Lee, J. J., Yang, D. H., Park, Y. H., Do, Y. R., Shin, H. J., Kim, M. K., Hyun, M. S., Sohn, S. K. (2006) FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108, 2720–2725
33. Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H. M., Borucka, E., Lurje, G., Sherrod, A. E., Iqbal, S., Groshen, S., Lenz, H. J. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25, 3712–3718
34. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., Neri, T. M., Ardizzoni, A. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789–1796
35. Weng, W. K., Levy, R. (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk. Lymphoma 50, 723–727
36. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., Sabourin, J. C., Boissiére-Michot, F. (2009) Impact of FcgammaRIIa- FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122–1129
37. De Haij, S., Jansen, J. H., Boross, P., Beurskens, F. J., Bakema, J. E., Bos, D. L., Martens, A., Verbeek, J. S., Parren, P. W., van de Winkel, J. G., Leusen, J. H. (2010) In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70, 3209–3217
38. Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., Dobrovic, A. (2013) A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6, 1
39. Cheson, B. D. (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28, 3525–3530
40. Alduaij, W., Illidge, T. M. (2011) The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 117, 2993–3001
41. Cang, S., Mukhi, N., Wang, K., Liu, D. (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5, 64
42. Nimmerjahn, F., Ravetch, J. V. (2012) Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 12, 13
43. Golay, J., Semenzato, G., Rambaldi, A., Foá, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., Regazzi, M. (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5, 826–837
44. Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M., Klein, C. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12, 2031–2042
45. Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., Hopfner, K. P., Umaña, P., Niederfellner, G. (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5, 22–33
46. Rafiq, S., Butchar, J. P., Cheney, C., Mo, X., Trotta, R., Caligiuri, M., Jarjoura, D., Tridandapani, S., Muthusamy, N., Byrd, J. C. (2013) Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190, 2702–2711
47. Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., Bousso, P. (2013) The mechanism of anti-CD20- mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123, 5098–5103
48. Stevenson, G. T. (2014) Three major uncertainties in the antibody therapy of cancer. Haematologica 99, 1538–1546
49. Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., Wu, Y., Meng, Y. G., Gribling, P., Lin, Z., Nguyen, K., Tran, T., Zhang, Y., Rosen, H., Martin, F., Chan, A. C. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817–826
50. Weitzman, J., Betancur, M., Boissel, L., Rabinowitz, A. P., Klein, A., Klingemann, H. (2009) Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 50, 1361–1368
51. Boross, P., Jansen, J. H., de Haij, S., Beurskens, F. J., van der Poel, C. E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J. G., Parren, P. W., Leusen, J. H. (2011) The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96, 1822–1830
52. Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L., Kubes, P., van Egmond, M. (2014) Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124, 812–823
53. Beum, P. V., Lindorfer, M. A., Taylor, R. P. (2008) Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 181, 2916–2924
54. Beum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J., Engelberts, P. J., Parren, P. W., van de Winkel, J. G., Taylor, R. P. (2011) Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187, 3438–3447
55. Boross, P., Jansen, J. H., Pastula, A., van der Poel, C. E., Leusen, J. H. (2012) Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol. Lett. 143, 44–52
56. Vaughan, A. T., Iriyama, C., Beers, S. A., Chan, C. H., Lim, S. H., Williams, E. L., Shah, V., Roghanian, A., Frendéus, B., Glennie, M. J., Cragg, M. S. (2014) Inhibitory FcgRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 123, 669–677
57. Wang, S. Y., Racila, E., Taylor, R. P., Weiner, G. J. (2008) NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111, 1456–1463
58. Racila, E., Link, B. K., Weng, W. K., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J., Dahle, C., Halwani, A., Levy, R., Weiner, G. J. (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 14, 6697–6703
59. Wang, S. Y., Veeramani, S., Racila, E., Cagley, J., Fritzinger, D. C., Vogel, C. W., St John, W., Weiner, G. J. (2009) Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 114, 5322–5330
60. Bonavida, B. (2014) Postulated mechanisms of resistance of B-cell non- Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin. Oncol. 41, 667–677
61. Trinchieri, G. (1989) Biology of natural killer cells. Adv. Immunol. 47, 187–376
62. Robertson, M. J., Ritz, J. (1990) Biology and clinical relevance of human natural killer cells. Blood 76, 2421–2438
63. Knorr, D. A., Bachanova, V., Verneris, M. R., Miller, J. S. (2014) Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26, 161–172
64. Chretien, A. S., Le Roy, A., Vey, N., Prebet, T., Blaise, D., Fauriat, C., Olive, D. (2014) Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front. Immunol. 5, 122
65. Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., Raulet, D. H. (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 122, 91–128
66. Moretta, L., Montaldo, E., Vacca, P., Del Zotto, G., Moretta, F., Merli, P., Locatelli, F., Mingari, M. C. (2014) Human natural killer cells: origin, receptors, function, and clinical applications. Int. Arch. Allergy Immunol. 164, 253–264
67. Huntington, N. D., Vosshenrich, C. A., Di Santo, J. P. (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703–714
68. Sun, J. C., Lanier, L. L. (2011) NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat. Rev. Immunol. 11, 645–657
69. Yu, J., Freud, A. G., Caligiuri, M. A. (2013) Location and cellular stages of natural killer cell development. Trends Immunol. 34, 573–582
70. Hwang, I., Zhang, T., Scott, J. M., Kim, A. R., Lee, T., Kakarla, T., Kim, A., Sunwoo, J. B., Kim, S. (2012) Identification of human NK cells that are deficient for signaling adaptor FcRg and specialized for antibodydependent immune functions. Int. Immunol. 24, 793–802
71. Zhang, T., Scott, J. M., Hwang, I., Kim, S. (2013) Cutting edge: antibodydependent memory-like NK cells distinguished by FcRg deficiency. J. Immunol. 190, 1402–1406
72. Lee, J., Zhang, T., Hwang, I., Kim, A., Nitschke, L., Kim, M., Scott, J. M., Kamimura, Y., Lanier, L. L., Kim, S. (2015) Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442
73. Min-Oo, G., Kamimura, Y., Hendricks, D. W., Nabekura, T., Lanier, L. L. (2013) Natural killer cells: walking three paths down memory lane. Trends Immunol. 34, 251–258
74. Sun, J. C., Ugolini, S., Vivier, E. (2014) Immunological memory within the innate immune system. EMBO J. 33, 1295–1303
75. Jha, P., Golovko, D., Bains, S., Hostetter, D., Meier, R., Wendland, M. F., Daldrup-Link, H. E. (2010) Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res. 70, 6109–6113
76. Carrega, P., Ferlazzo, G. (2012) Natural killer cell distribution and trafficking in human tissues. Front. Immunol. 3, 347
77. Bernardini, G., Sciumé, G., Santoni, A. (2013) Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front. Immunol. 4, 12
78. Sta Maria, N. S., Barnes, S. R., Jacobs, R. E. (2014) In vivo monitoring of natural killer cell trafficking during tumor immunotherapy. Magn. Reson. Insights 7, 15–21
79. Deguine, J., Breart, B., Lemaître, F., Di Santo, J. P., Bousso, P. (2010) Intravital imaging reveals distinct dynamics for natural killer and CD8 (+) T cells during tumor regression. Immunity 33, 632–644
80. Bottino, C., Moretta, L., Moretta, A. (2006) NK cell activating receptors and tumor recognition in humans. Curr. Top. Microbiol. Immunol. 298, 175–182
81. Lanier, L. L. (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502
82. Long, E. O., Kim, H. S., Liu, D., Peterson, M. E., Rajagopalan, S. (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31, 227–258
83. Campbell, K. S., Hasegawa, J. (2013) Natural killer cell biology: an update and future directions. J. Allergy Clin. Immunol. 132, 536–544
84. Benson, D. M., Caligiuri, M. A. (2014) Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol. Res. 2, 99–104
85. Martinet, L., Smyth, M. J. (2015) Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243–254
86. Wiemann, K., Mittr ücker, H. W., Feger, U., Welte, S. A., Yokoyama, W. M., Spies, T., Rammensee, H. G., Steinle, A. (2005) Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175, 720–729
87. Fuchs, A., Colonna, M. (2006) The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin. Cancer Biol. 16, 359–366
88. Eagle, R. A., Trowsdale, J. (2007) Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7, 737–744
89. Nausch, N., Cerwenka, A. (2008) NKG2D ligands in tumor immunity. Oncogene 27, 5944–5958
90. Burgess, S. J., Maasho, K., Masilamani, M., Narayanan, S., Borrego, F., Coligan, J. E. (2008) The NKG2D receptor: immunobiology and clinical implications. Immunol. Res. 40, 18–34
91. Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. M., Raulet, D. H. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571–580
92. Xu, Z., Jin, B. (2010) A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell. Mol. Immunol. 7, 11–19
93. Morisaki, T., Onishi, H., Katano, M. (2012) Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res. 32, 2241–2247
94. Chan, C. J., Andrews, D. M., Smyth, M. J. (2012) Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr. Opin. Immunol. 24, 246–251
95. Spear, P., Wu, M. R., Sentman, M. L., Sentman, C. L. (2013) NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8
96. Ullrich, E., Koch, J., Cerwenka, A., Steinle, A. (2013) New prospects on the NKG2D/NKG2DL system for oncology. OncoImmunology 2, e26097
97. El-Gazzar, A., Groh, V., Spies, T. (2013) Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J. Immunol. 191, 1509–1515
98. Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., Jung, H. (2013) Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413–441
99. Le Bert, N., Gasser, S. (2014) Advances in NKG2D ligand recognition and responses by NK cells. Immunol. Cell Biol. 92, 230–236
100. De Andrade, L. F., Smyth, M. J., Martinet, L. (2014) DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol. Cell Biol. 92, 237–244
101. Huergo-Zapico, L., Acebes-Huerta, A., López-Soto, A., Villa-Álvarez, M., Gonzalez-Rodriguez, A. P., Gonzalez, S. (2014) Molecular bases for the regulation of NKG2D ligands in cancer. Front. Immunol. 5, 106
102. Cerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., Santoni, A. (2014) The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front. Immunol. 4, 508
103. Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., Stern-Ginossar, N., Tsukerman, P., Jonjic, S., Mandelboim, O. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 17858–17863
104. Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., Smyth, M. J. (2014) The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431–438
105. Trinchieri, G., Valiante, N. (1993) Receptors for the Fc fragment of IgG on natural killer cells. Nat. Immun. 12, 218–234
106. Perussia, B. (1998) Fc receptors on natural killer cells. Curr. Top. Microbiol. Immunol. 230, 63–88
107. Bryceson, Y. T., March, M. E., Ljunggren, H. G., Long, E. O. (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107, 159–166
108. Dunn, G. P., Koebel, C. M., Schreiber, R. D. (2006) Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848
109. Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., Smyth, M. J. (2002) Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3, 83–90
110. Mocikat, R., Braumüller, H., Gumy, A., Egeter, O., Ziegler, H., Reusch, U., Bubeck, A., Louis, J., Mailhammer, R., Riethmüller, G., Koszinowski, U., Röcken, M. (2003) Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561–569
111. Martín-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., Sallusto, F. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5, 1260–1265
112. Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., Vivier, E. (2005) Natural-killer cells and dendritic cells: “l’union fait la force”. Blood 106, 2252–2258
113. Van Elssen, C. H., Oth, T., Germeraad, W. T., Bos, G. M., Vanderlocht, J. (2014) Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin. Cancer Res. 20, 1095–1103
114. Bouwer, A. L., Saunderson, S. C., Caldwell, F. J., Damani, T. T., Pelham, S. J., Dunn, A. C., Jack, R. W., Stoitzner, P., McLellan, A. D. (2014) NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J. Immunol. 192, 2514–2521
115. Fischer, L., Penack, O., Gentilini, C., Nogai, A., Muessig, A., Thiel, E., Uharek, L. (2006) The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp. Hematol. 34, 753–759
116. Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., Thibault, G. (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64, 4664–4669
117. Bowles, J. A., Weiner, G. J. (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 304, 88–99
118. Bowles, J. A., Wang, S. Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M. A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., Breitmeyer, J. B., Weiner, G. J. (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108, 2648–2654
119. Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., Dimmock, E. A., Kortsaris, A., Mitsiades, C., Anderson, K. C., Fox, E. A., Treon, S. P. (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V/V and V/F polymorphism. Blood 110, 2561–2564
120. Veeramani, S., Wang, S. Y., Dahle, C., Blackwell, S., Jacobus, L., Knutson, T., Button, A., Link, B. K., Weiner, G. J. (2011) Rituximab infusion induces NK activation in lymphoma patients with the highaffinity CD16 polymorphism. Blood 118, 3347–3349
121. Zent, C. S., Taylor, R. P., Lindorfer, M. A., Beum, P. V., LaPlant, B., Wu, W., Call, T. G., Bowen, D. A., Conte, M. J., Frederick, L. A., Link, B. K., Blackwell, S. E., Veeramani, S., Baig, N. A., Viswanatha, D. S., Weiner, G. J., Witzig, T. E. (2014) Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am. J. Hematol. 89, 757–765
122. Rudnicka, D., Oszmiana, A., Finch, D. K., Strickland, I., Schofield, D. J., Lowe, D. C., Sleeman, M. A., Davis, D. M. (2013) Rituximab causes a polarization of B cells that augments its therapeutic function in NKcell- mediated antibody-dependent cellular cytotoxicity. Blood 121, 4694–4702
123. Vega, M. I., Huerta-Yepez, S., Jazirehi, A. R., Garban, H., Bonavida, B. (2005) Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24, 8114–8127
124. Vega, M. I., Baritaki, S., Huerta-Yepez, S., Martinez-Paniagua, M. A., Bonavida, B. (2011) A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leuk. Lymphoma 52, 108–121
125. Borgerding, A., Hasenkamp, J., Engelke, M., Burkhart, N., Trümper, L., Wienands, J., Glass, B. (2010) B-Lymphoma cells escape rituximabtriggered elimination by NK cells through increased HLA class I expression. Exp. Hematol. 38, 213–221
126. Chan, W. K., Kung Sutherland, M., Li, Y., Zalevsky, J., Schell, S., Leung, W. (2012) Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin. Cancer Res. 18, 6296–6305
127. Tarek, N., Le Luduec, J. B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N. K., Hsu, K. C. (2012) Unlicensed NK cells target neuroblastoma following anti- GD2 antibody treatment. J. Clin. Invest. 122, 3260–3270
128. Terszowski, G., Klein, C., Stern, M. (2014) KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J. Immunol. 192, 5618–5624
129. Du, J., Lopez-Verges, S., Pitcher, B. N., Johnson, J., Jung, S. H., Zhou, L., Hsu, K., Czuczman, M. S., Cheson, B., Kaplan, L., Lanier, L. L., Venstrom, J. M. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol. Res. 2, 878–889
130. Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, E., Romagné, F., Levy, R., Bléry, M., André, P. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678–686
131. Nijhof, I. S., Lammerts van Bueren, J. J., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W., Parren, P. W., Mutis, T. (2015) Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 100, 263–268
132. Inagaki, A., Ishida, T., Yano, H., Ishii, T., Kusumoto, S., Ito, A., Ri, M., Mori, F., Ding, J., Komatsu, H., Iida, S., Ueda, R. (2009) Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int. J. Cancer 125, 212–221
133. Deguine, J., Breart, B., Lemaˆıtre, F., Bousso, P. (2012) Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions. J. Immunol. 189, 5493–5497
134. Mentlik James, A., Cohen, A. D., Campbell, K. S. (2013) Combination immune therapies to enhance anti-tumor responses by NK cells. Front. Immunol. 4, 481
135. Kellner, C., Hallack, D., Glorius, P., Staudinger, M., Mohseni Nodehi, S., de Weers, M., van de Winkel, J. G., Parren, P. W., Stauch, M., Valerius, T., Repp, R., Humpe, A., Gramatzki, M., Peipp, M. (2012) Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cellmediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26, 830–834
136. Soriani, A., Fionda, C., Ricci, B., Iannitto, M. L., Cippitelli, M., Santoni, A. (2013) Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. OncoImmunology 2, e26663
137. Selenko, N., Maidic, O., Draxier, S., Berer, A., Jäger, U., Knapp, W., Stöckl, J. (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and crosspriming of CD8+ cytotoxic T cells. Leukemia 15, 1619–1626
138. Hilchey, S. P., Hyrien, O., Mosmann, T. R., Livingstone, A. M., Friedberg, J. W., Young, F., Fisher, R. I., Kelleher, Jr., R. J., Bankert, R. B., Bernstein, S. H. (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 113, 3809–3812
139. Abés, R., Gélizé, E., Fridman, W. H., Teillaud, J. L. (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116, 926–934
140. Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., Ferris, R. L. (2011) Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol. Res. 50, 248–254
141. Trivedi, S., Jie, H. B., Ferris, R. L. (2014) Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin. Oncol. 41, 678–684
142. Elliott, J. M., Yokoyama, W. M. (2011) Unifying concepts of MHCdependent natural killer cell education. Trends Immunol. 32, 364–372
143. Narni-Mancinelli, E., Ugolini, S., Vivier, E. (2013) Tuning the threshold of natural killer cell responses. Curr. Opin. Immunol. 25, 53–58
144. Shifrin, N., Raulet, D. H., Ardolino, M. (2014) NK cell self tolerance, responsiveness and missing self recognition. Semin. Immunol. 26, 138–144
145. Harrison, D., Phillips, J. H., Lanier, L. L. (1991) Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J. Immunol. 147, 3459–3465
146. Grzywacz, B., Kataria, N., Verneris, M. R. (2007) CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21, 356–359, author reply 359
147. Peruzzi, G., Femnou, L., Gil-Krzewska, A., Borrego, F., Weck, J., Krzewski, K., Coligan, J. E. (2013) Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J. Immunol. 191, 1883–1894
148. Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., Miller, J. (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599–3608
149. Lajoie, L., Congy-Jolivet, N., Bolzec, A., Gouilleux-Gruart, V., Sicard, E., Sung, H. C., Peiretti, F., Moreau, T., Vié H., Clémenceau, B., Thibault, G. (2014) ADAM17-mediated shedding of FcgRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J. Immunol. 192, 741–751
150. Parsons, M. S., Tang, C. C., Jegaskanda, S., Center, R. J., Brooks, A. G., Stratov, I., Kent, S. J. (2014) Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J. Immunol. 192, 308–315
151. Tripathy, S. K., Keyel, P. A., Yang, L., Pingel, J. T., Cheng, T. P., Schneeberger, A., Yokoyama, W. M. (2008) Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J. Exp. Med. 205, 1829–1841
152. Coudert, J. D., Scarpellino, L., Gros, F., Vivier, E., Held, W. (2008) Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111, 3571–3578
153. Fauriat, C., Ivarsson, M. A., Ljunggren, H. G., Malmberg, K. J., Michaëlsson, J. (2010) Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115, 1166–1174
154. Bolanos, F. D., Tripathy, S. K. (2011) Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible. J. Immunol. 186, 2765–2771
155. Capuano, C., Romanelli, M., Pighi, C., Molfetta, R., Paolini, R., Santoni, A., Galandrini, R. (2013) CD16 aggregation induced by therapeutic antibody-opsonised targets impairs cytotoxic responses in human NK cells. Front. Immunol. 4, 148
156. Molfetta, R., Quatrini, L., Gasparrini, F., Zitti, B., Santoni, A., Paolini, R. (2014) Regulation of fc receptor endocytic trafficking by ubiquitination. Front. Immunol. 5, 449
157. Molfetta, R., Quatrini, L., Capuano, C., Gasparrini, F., Zitti, B., Zingoni, A., Galandrini, R., Santoni, A., Paolini, R. (2014) c-Cbl regulates MICAbut not ULBP2-induced NKG2D down-modulation in human NK cells. Eur. J. Immunol. 44, 2761–2770
158. Cox, M. C., Battella, S., La Scaleia, R., Pelliccia, S., Di Napoli, A., Porzia, A., Cecere, F., Alma, E., Zingoni, A., Mainiero, F., Ruco, L., Monarca, B., Santoni, A., Palmieri, G. (2015) Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. OncoImmunology 4, e990773
159. Beurskens, F. J., Lindorfer, M. A., Farooqui, M., Beum, P. V., Engelberts, P., Mackus, W. J., Parren, P. W., Wiestner, A., Taylor, R. P. (2012) Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 188, 3532–3541
160. Le Garff-Tavernier, M., Decocq, J., de Romeuf, C., Parizot, C., Dutertre, C. A., Chapiro, E., Davi, F., Debré, P., Prost, J. F., Teillaud, J. L., Merle- Beral, H., Vieillard, V. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 25, 101–109
161. Suresh, T., Lee, L. X., Joshi, J., Barta, S. K. (2014) New antibody approaches to lymphoma therapy. J. Hematol. Oncol. 7, 58
162. Nelson, M. H., Paulos, C. M. (2015) Novel immunotherapies for hematologic malignancies. Immunol. Rev. 263, 90–105
163. Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., Miller, J. S. (2012) Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674–2684
164. Miller, J. S. (2013) Therapeutic applications: natural killer cells in the clinic. Hematology (Am Soc Hematol Educ Program) 2013, 247–253
165. Reiners, K. S., Kessler, J., Sauer, M., Rothe, A., Hansen, H. P., Reusch, U., Hucke, C., Köhl, U., Dürkop, H., Engert, A., von Strandmann, E. P. (2013) Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol. Ther. 21, 895–903
166. Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., Vallera, D. A., Miller, J. S. (2013) Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844–3855
167. Lameris, R., de Bruin, R. C., Schneiders, F. L., van Bergen en Henegouwen, P. M., Verheul, H. M., de Gruijl, T. D., van der Vliet, H. J. (2014) Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 92, 153–165
168. Raab, S., Steinbacher, J., Schmiedel, B. J., Kousis, P. C., Steinle, A., Jung, G., Grosse-Hovest, L., Salih, H. R. (2014) Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J. Immunol. 193, 4261–4272
169. Steinbacher, J., Baltz-Ghahremanpour, K., Schmiedel, B. J., Steinle, A., Jung, G., Kübler, A., André, M. C., Grosse-Hovest, L., Salih, H. R. (2015) An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Int. J. Cancer 136, 1073–1084
170. Von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., Hallek, M., Engert, A. (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107, 1955–1962
171. Rothe, A., Jachimowicz, R. D., Borchmann, S., Madlener, M., Keßler, J., Reiners, K. S., Sauer, M., Hansen, H. P., Ullrich, R. T., Chatterjee, S., Borchmann, P., Yazaki, P., Koslowsky, T. C., Engert, A., Heukamp, L. C., Hallek, M., von Strandmann, E. P. (2014) The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int. J. Cancer 134, 2829–2840
172. Lindorfer, M. A., Wiestner, A., Zent, C. S., Taylor, R. P. (2012) Monoclonal antibody (mAb)-based cancer therapy: is it time to reevaluate dosing strategies? OncoImmunology 1, 959–961
173. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., Zitvogel, L. (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9, 486–494
174. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L. (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252
175. Cheng, M., Chen, Y., Xiao, W., Sun, R., Tian, Z. (2013) NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 10, 230–252
176. Carson, W. E., Parihar, R., Lindemann, M. J., Personeni, N., Dierksheide, J., Meropol, N. J., Baselga, J., Caligiuri, M. A. (2001) Interleukin-2 enhances the natural killer cell response to Herceptincoated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31, 3016–3025
177. Repka, T., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V. K., Yee, D., Miller, J. S. (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin. Cancer Res. 9, 2440–2446
178. Eisenbeis, C. F., Grainger, A., Fischer, B., Baiocchi, R. A., Carrodeguas, L., Roychowdhury, S., Chen, L., Banks, A. L., Davis, T., Young, D., Kelbick, N., Stephens, J., Byrd, J. C., Grever, M. R., Caligiuri, M. A., Porcu, P. (2004) Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin. Cancer Res. 10, 6101–6110
179. Lopes de Menezes, D. E., Denis-Mize, K., Tang, Y., Ye, H., Kunich, J. C., Garrett, E. N., Peng, J., Cousens, L. S., Gelb, A. B., Heise, C., Wilson, S. E., Jallal, B., Aukerman, S. L. (2007) Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J. Immunother. 30, 64–74
180. Bhat, R., Watzl, C. (2007) Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies. PLoS One 2, e326
181. Moga, E., Cantó, E., Vidal, S., Juarez, C., Sierra, J., Briones, J. (2011) Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp. Hematol. 39, 1064–1071
182. Eskelund, C. W., Nederby, L., Thysen, A. H., Skovbo, A., Roug, A. S., Hokland, M. E. (2011) Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia. Leuk. Res. 35, 914–920
183. Laprevotte, E., Voisin, G., Ysebaert, L., Klein, C., Daugrois, C., Laurent, G., Fournie, J. J., Quillet-Mary, A. (2013) Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J. Immunol. 191, 3634–3640
184. Waldmann, T. A. (2015) The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3, 219–227
185. Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 10, 4839–4847
186. Buhtoiarov, I. N., Neal, Z. C., Gan, J., Buhtoiarova, T. N., Patankar, M. S., Gubbels, J. A., Hank, J. A., Yamane, B., Rakhmilevich, A. L., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. (2011) Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J. Leukoc. Biol. 89, 625–638
187. Parihar, R., Dierksheide, J., Hu, Y., Carson, W. E. (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J. Clin. Invest. 110, 983–992
188. Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Haskova, Z., Whitacre, M., Trulli, S., Chen, Y. J., Toso, J., Jonak, Z. L., Chang, H. C., Robertson, M. J. (2013) Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol. Immunother. 62, 1073–1082
189. Laprevotte, E., Ysebaert, L., Klein, C., Valleron, W., Blanc, A., Gross, E., Laurent, G., Fournié, J. J., Quillet-Mary, A. (2013) Endogenous IL- 8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leuk. Res. 37, 440–446
190. Chester, C., Marabelle, A., Houot, R., Kohrt, H. E. (2015) Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Curr. Opin. Immunol. 33, 1–8
191. Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M. P., Chen, L., Tedder, T. F., Levy, R. (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423–2432
192. Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W. K., Clarke, M. F., Carlson, R. W., Stockdale, F. E., Mollick, J. A., Chen, L., Levy, R. (2012) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122, 1066–1075
193. Houot, R., Kohrt, H., Levy, R. (2012) Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. OncoImmunology 1, 957–958
194. Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, A., Hebb, J., Chester, C., Waller, E., Ostashko, A., Weng, W. K., Chen, L., Czerwinski, D., Fu, Y. X., Sunwoo, J., Levy, R. (2014) Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124, 2668–2682
195. Houot, R., Kohrt, H. (2014) CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. OncoImmunology 3, e941740
196. Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S., Weiner, L. M. (2008) Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of antilymphoma therapy. J. Immunol. 180, 6392–6401
197. Thielens, A., Vivier, E., Romagné, F. (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24, 239–245
198. Reeder, C. B., Ansell, S. M. (2011) Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 117, 1453–1462
199. Roschewski, M., Staudt, L. M., Wilson, W. H. (2014) Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat. Rev. Clin. Oncol. 11, 12–23
200. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J. B. (2008) lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 14, 4650–4657
201. Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J. B., Yi, Q., Wang, M. (2009) Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am. J. Hematol. 84, 553–559
202. Wu, L., Parton, A., Lu, L., Adams, M., Schafer, P., Bartlett, J. B. (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol. Immunother. 60, 61–73
203. Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S. K., Takeda, K., Zitvogel, L., Martinet, L., Smyth, M. J. (2014) Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 74, 7298–7308
204. Krusch, M., Salih, J., Schlicke, M., Baessler, T., Kampa, K. M., Mayer, F., Salih, H. R. (2009) The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J. Immunol. 183, 8286–8294
205. Da Roit, F., Engelberts, P. J., Taylor, R. P., Breij, E. C., Gritti, G., Rambaldi, A., Introna, M., Parren, P. W., Beurskens, F. J., Golay, J. (2015) Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 100, 77–86
206. Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., Johnson, A. J., Byrd, J. C. (2014) Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 123, 1957–1960
207. Winiarska, M., Bojarczuk, K., Pyrzynska, B., Bil, J., Siernicka, M., Dwojak, M., Bobrowicz, M., Miazek, N., Zapala, P., Zagozdzon, A., Krol, M., Syta, A., Podszywalow-Bartnicka, P., Pilch, Z., Dabrowska-Iwanicka, A., Juszczynski, P., Efremov, D. G., Slabicki, M., Zenz, T., Le Roy, A., Olive, D., Rygiel, T. P., Leusen, J. H., Golab, J. (2014) Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs 6, 1300–1313
208. Berdeja, J. G., Hess, A., Lucas, D. M., O’Donnell, P., Ambinder, R. F., Diehl, L. F., Carter-Brookins, D., Newton, S., Flinn, I. W. (2007) Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin. Cancer Res. 13, 2392–2399
209. Pievani, A., Belussi, C., Klein, C., Rambaldi, A., Golay, J., Introna, M. (2011) Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti- CD20 antibodies. Blood 117, 510–518
210. Leung, W. (2014) Infusions of allogeneic natural killer cells as cancer therapy. Clin. Cancer Res. 20, 3390–3400
211. Naidoo, J., Page, D. B., Wolchok, J. D. (2014) Immune modulation for cancer therapy. Br. J. Cancer 111, 2214–2219
212. Smith, E. L., Zamarin, D., Lesokhin, A. M. (2014) Harnessing the immune system for cancer therapy. Curr. Opin. Oncol. 26, 600–607
213. Postow, M. A., Callahan, M. K., Wolchok, J. D. (2015) Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982
214. Topalian, S. L., Drake, C. G., Pardoll, D. M. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461
215. Shin, D. S., Ribas, A. (2015) The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr. Opin. Immunol. 33, 23–35
216. Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L.W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., Feng, L., Baladandayuthapani, V., Wang, Z., Ma, W., Gao, Y., Wallace, M., Vence, L. M., Radvanyi, L., Muzzafar, T., Rotem-Yehudar, R., Davis, R. E., Neelapu, S. S. (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69–77.